Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bovine whey immunoglobulin-rich fraction is a biologic nutraceutical derived from cow's milk whey, enriched with immunoglobulins (primarily IgG). It is designed for oral administration to modulate the immune system via the gut-skin axis. In a pilot clinical study conducted by Griffith University, this fraction was evaluated in combination with Glycomax lactoferrin for the treatment of atopic dermatitis. The study, published in the *Journal of Dermatological Science* in 2017, reported significant improvements in SCORAD and DLQI scores, suggesting its potential as a therapeutic supplement for managing inflammatory skin conditions by influencing intestinal immunity and systemic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bovine whey immunoglobulin-rich fraction.